The independent source for health policy research, polling, and news.
501-520 of 1,313 results
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
The data is reassuring to people who got this shot.
The approach, known as contingency management, has helped thousands of veterans kick the methedrine habit, but a federal government ruling has limited its use. California hopes to challenge that and make the treatment a Medi-Cal benefit.
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive drug that might (or might not) slow the progression of Alzheimer鈥檚 disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, 鈥淣ever Pay the First Bill: And Other Ways to Fight the Health Care System and Win.鈥
As more independently owned community pharmacies close, a Colorado town is crowdsourcing ways of getting prescription medicines delivered to those who can鈥檛 travel the long distance to the closest pharmacy. But even those stopgap measures don鈥檛 always work.
In an ongoing effort to control prescription drug costs, states are targeting the companies that mediate deals among drug manufacturers, health insurers and pharmacies. The pharmacy benefit managers say they negotiate lower prices for patients, yet the nitty-gritty occurs largely behind a curtain that lawmakers are trying to pull back.
Democrats in Congress and the states are devising strategies to expand health coverage 鈥 through the Affordable Care Act, Medicare, Medicaid and a 鈥減ublic option.鈥 But progress remains halting, at best. Meanwhile, lawmakers in Washington may have to agree on how to control prescription drug prices if they wish to finance their coverage initiatives. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Shefali Luthra of The 19th join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Michelle Andrews, who reported and wrote last month鈥檚 KHN-NPR 鈥淏ill of the Month鈥 episode about a very expensive sleep study.
The scientific literature shows that natural immunity does provide protection against covid-19, but experts say getting vaccinated can provide additional protection against variants.
Federal officials say that some of the money changing hands has corrupted doctors and endangered patients.
The federal approval of a controversial drug to treat Alzheimer鈥檚 disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast鈥檚 200th episode, the panelists discuss what has surprised them most and least over the past four years.
Safety-net clinics especially are bracing for how the drugmaker鈥檚 policy shift could reduce their budgets and hamstring their ability to provide care to an at-risk population.
As vaccine expiration dates loom, states with hundreds of thousands of doses on hand say demand is tanking and there鈥檚 no easy way to donate to other states or countries that might want them
The agency is to decide by June 7 whether to greenlight Biogen鈥檚 drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it鈥檚 hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss the prospects for policy changes.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it鈥檚 unclear when or if the FDA would approve any state鈥檚 importation plan.
In big cities and small towns, opioid use among some young hip-hop fans is about emulating their favorite rap star鈥檚 image 鈥 while paying little attention to the serious consequences.
Lawmakers are working on fleshing out the concept of a 鈥減ublic option,鈥 a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
漏 2026 51视频